Frestedt Joy L, Walsh Melanie, Kuskowski Michael A, Zenk John L
Clinical Affairs Department, Minnesota Applied Research Center, Edina, Minneapolis, USA.
Nutr J. 2008 Feb 17;7:9. doi: 10.1186/1475-2891-7-9.
This small, pilot study evaluated the impact of treatment with a natural multi-mineral supplement from seaweed (Aquamin) on walking distance, pain and joint mobility in subjects with moderate to severe osteoarthritis of the knee.
Subjects (n = 70) with moderate to severe osteoarthritis of the knee were randomized to four double-blinded treatments for 12 weeks: (a) Glucosamine sulfate (1500 mg/d); (b) Aquamin (2400 mg/d); (c) Combined treatment composed of Glucosamine sulfate (1500 mg/d) plus Aquamin (2400 mg/d) and (d) Placebo. Primary outcome measures were WOMAC scores and 6 Minute Walking Distances (6 MWD). Laboratory based blood tests were used as safety measures.
Fifty subjects completed the study and analysis of the data showed significant differences between the groups for changes in WOMAC pain scores over time (p = 0.009 ANCOVA); however, these data must be reviewed with caution since significant differences were found between the groups at baseline for WOMAC pain and stiffness scores (p = 0.0039 and p = 0.013, respectively, ANOVA). Only the Aquamin and Glucosamine groups demonstrated significant improvements in symptoms over the course of the study. The combination group (like the placebo group) did not show any significant improvements in OA symptoms in this trial. Within group analysis demonstrated significant improvements over time on treatment for the WOMAC pain, activity, composite and stiffness (Aquamin only) scores as well as the 6 minute walking distances for subjects in the Aquamin and Glucosamine treatment groups. The Aquamin and Glucosamine groups walked 101 feet (+7%) and 56 feet (+3.5%) extra respectively. All treatments were well tolerated and the adverse events profiles were not significantly different between the groups.
This small preliminary study suggested that a multi mineral supplement (Aquamin) may reduce the pain and stiffness of osteoarthritis of the knee over 12 weeks of treatment and warrants further study.
ClinicalTrials.gov number: NCT00452101.
这项小型试点研究评估了使用一种来自海藻的天然多矿物质补充剂（Aquamin）对中度至重度膝关节骨关节炎患者步行距离、疼痛及关节活动度的影响。
70名中度至重度膝关节骨关节炎患者被随机分为四组，进行为期12周的双盲治疗：（a）硫酸葡萄糖胺（1500毫克/天）；（b）Aquamin（2400毫克/天）；（c）硫酸葡萄糖胺（1500毫克/天）加Aquamin（2400毫克/天）的联合治疗；（d）安慰剂。主要结局指标为WOMAC评分和6分钟步行距离（6MWD）。基于实验室的血液检测用作安全指标。
50名受试者完成了研究，数据分析显示，随着时间推移，各治疗组WOMAC疼痛评分变化存在显著差异（协方差分析，p = 0.009）；然而，这些数据必须谨慎审视，因为在基线时，各治疗组的WOMAC疼痛和僵硬评分存在显著差异（方差分析，p分别为0.0039和0.013）。在研究过程中，只有Aquamin组和硫酸葡萄糖胺组的症状有显著改善。联合治疗组（与安慰剂组一样）在该试验中未显示出骨关节炎症状有任何显著改善。组内分析表明，随着时间推移，Aquamin和硫酸葡萄糖胺治疗组受试者的WOMAC疼痛、活动能力综合评分、僵硬评分（仅Aquamin组）以及6分钟步行距离均有显著改善。Aquamin组和硫酸葡萄糖胺组分别多走了101英尺（+7%）和56英尺（+3.5%）。所有治疗耐受性良好，各治疗组的不良事件情况无显著差异。
这项小型初步研究表明，一种多矿物质补充剂（Aquamin）在12周的治疗过程中可能减轻膝关节骨关节炎的疼痛和僵硬，值得进一步研究。
ClinicalTrials.gov编号：NCT00452101。
